Category: Technology Licenses
Created On: 2022-04-28
Record Count: 14
- Wound Care
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 372627
Licensor grants an exclusive worldwide license under the Licensed Technology to use, offer to sell, sell, and otherwise commercialize, solely in the Field of Use and the Field of Extended Use, Licensed Products which include rhPDGF-BB purchased from Licensor.
For the Sublicenses, Licensor grants the right to grant sublicenses under the Licensed Technology to Distributors to use, offer to sell and sell, in the Field of Use and the Field of Extended Use, Licensed Products purchased from Licensor.
Proven rhPDGF technology is FDA approval of GEM 21S for periodontal bone regeneration suggests potential for efficacy in other bone and musculoskeletal applications.
GEM 21SÂ® growth-factor enhanced matrix is indicated to treat the following periodontally related defects intrabony periodontal defects; furcation periodontal defects; and gingival recession associated with periodontal defects.
GEM 21SÂ® growth-factor enhanced matrix combines a bioactive protein â€“ highly purified rhPDGF-BB â€“ with an osteoconductive matrix, ÃŸ-TCP.
GEM 21SÂ® is the only dental therapy containing rhPDGF-BB, one of the main growth factors found in the human body and well known for its stimulatory role in wound healing.
This completely synthetic grafting system is engineered to stimulate wound healing and bone regeneration when implanted in the body by triggering a cascade of molecular events that continues on even after the implanted rhPDGF-BB is gone.
The Field of Use means all uses related to the treatment, cure, or relief of mammals for periodontal diseases and/or the repair, restoration or reconstruction of oral and cranioâ€¢ maxillofacial osseous defects.
The Field of Extended Use shall mean all uses outside the Field of Use that are related to the treatment and healing of bone, cartilage, tendon and ligaments of the skeletal tissue system in animals, excluding humans, excluding the treatment and healing of soft tissue wounds.
IPSCIO Record ID: 227278
U.S.P.N. 5,019,559 – Wound healing using PDGF and IGF-II
U.S.P.N. 4,861,757 – Wound healing and bone regeneration using PDGF and IGF-I
U .S.P.N. 5,124,316 – Method for periodontal regeneration
U.S.P.N. 4,874,746 – Wound healing composition of TGF-alpha and PDGF
U .S.P .N. 4,983,581 – Wound healing composition of IGF-I and TGF-.beta.
U.S.P.N. 5,256,644 – Wound healing using IGF-II and TGF
U.S.P,N. 5,034,375 – Process of wound healing using PDGF and EGF
U.S.P.N. 5,035,887 – Wound healing composition of IL-1 and PDGF or IGF-1
U.S.P.N. 5,516,699 – Pyridinoline crosslinks as markers of periodontal and peri-implant disease activity
rhPDGF is a bio-active protein that is a key mediator of wound healing and tissue regeneration.
IPSCIO Record ID: 372628
For the License, Licensor grants a worldwide license under the Licensed Technology to make, have made, use, offer to sell, sell, and otherwise commercialize Licensed Products, solely within the Field of Use.
For the Right to Grant Sublicenses, Licensor grants the right to grant sublicenses under the Licensed Technology to make, have made, use, offer to sell, sell, and otherwise commercialize Licensed Products within the Field of Use.
Platelet-Derived Growth Factor Compositions and Methods of Use Thereof;
Maxillofacial Bone Augmentation Using rhPDGF-BB and a Biocompatible Matrix;
Compositions and Methods for Repairing Cartilage Defects;
Compositions and Methods for Treating Bone;
Prevention and Treatment for Osteonecrosis and Osteonecrosis of the Jaw;
Methods and Compositions for Treating the Vertebral Column; and,
Compositions and Methods for Treating Rotator Cuff Injuries.
Licensor has certain assets related to the orofacial therapeutic business.
rhPDGF means recombinant human platelet derived growth factor.
Licensed Products means any product with application within the Field of Use that Licensor and/or Licensee develops or has developed which is covered by the Licensed Technology, developed through the use of a process which is covered by the Licensed Technology, or could not be manufactured, used or sold without the incorporation or use in whole or in part of some or all of the Licensed Technology, including, but not limited to
— any Growth Factor product, including GEM 21S, GEM ONJ, GEM 22A, and a GEM OS2-like product for application within the Field of Use, including Growth Factors alone, combinations of Growth Factors, and combinations of Growth Factors with non-Growth Factor products, and any component thereof, for which commercialization thereof is not subject to a third party license agreement that Licensor enters into after the Closing of the Asset Purchase Agreement;
— any device, e.g., bone matrix material, implant and/or related product, for which the commercialization thereof is not subject to a third party license agreement that Licensor enters into after the Closing of the Asset Purchase Agreement.
IPSCIO Record ID: 27675
IPSCIO Record ID: 5290
IPSCIO Record ID: 26656
IPSCIO Record ID: 226071
IPSCIO Record ID: 353934
Know-How License Licensor hereby grants to Licensee during the Term a nontransferable, nonsublicensable, exclusive right and license in the Field of Use under the Licensed Know-How to make, use, offer to sell, sell, and import Licensed Products.
Licensee hereby grants to Licensor a non-exclusive, nonsublicensable, nontransferable, worldwide, royalty-free, license to all Improvements for use by Licensor to make, use, sell, offer for sale and/or import Licensors products solely outside the Field of Use.
1 – METHODS OF DECELLULARIZING BONE Utility – NPREG
United States of America
2 – U.S. Provisional Patent Application entitled FISTULA FILLER AND DEPLOYMENT SYSTEM, Application No. 62/684,426; Filing Date June 13, 2018, U.S. PROVISIONAL CONVERSION/ PARIS CONVENTION DEADLINE JUNE 13, 2019
3 – U.S. Provisional Patent Application entitled IMPROVED DECELLULARIZATION OF ISOLATED ORGANS, Application No. 62/821,620
4 – U.S. Provisional Patent Application entitled NON-DESTRUCTIVE METHOD OF DEHYDRATION OF EXTRACELLULAR MATRIX OF DECELLULARIZED ORGANS AND PARTICLES FORMED THEREFROM, Application No. 62/789,218
Miromeshâ„¢ and MirodermTM products
and the following products in development or previously considered
Miromesh is a biological mesh made using perfusion decelluarized porcine liver for hernia repair applications. It is designed to be implanted to boost soft tissue.
MiroDermÂ® is a non-crosslinked acellular wound matrix, derived from the highly vascularized porcine liver. It is intended for the management of wounds, including partial and full-thickness wounds; pressure ulcers; chronic vascular ulcers; diabetic ulcers; tunneled, undermined wounds; trauma wounds; drainage wounds; and surgical wounds.
IPSCIO Record ID: 287764
The Companyâ€™s business is developing, marketing, and distributing wound and skin care products to physicians, hospitals, clinics and post-acute care settings.
IPSCIO Record ID: 26284
IPSCIO Record ID: 1232
IPSCIO Record ID: 245908
The patents are for Use of Nonâ€¢lmmunogenic Cartilage and Bone Suspension as Bulking Agents, Novel Osteopontin Derived Chemotactic Peptides and Methods of Use, Methods and Compositions for Programming an Organic Matrix for Remodeling into a Target Tissue, and, Osseointegration into Osteopontin and Hyaluronic Acid Coated Surfaces.
The Licensed Product shall mean any product and/or Licensed Process for the manufacture, development, use, lease, sale or import of which would infringe any one of the issued, unexpired claim(s) or any one of the pending claim(s) contained in the Patent Rights in any country, and/or the manufacture of which uses a Licensed Process.
Licensed Process shall mean any process that would infringe any one of the issued, unexpired claim(s) or any one of the pending claim(s) contained in the Patent Rights in any country.
The Field of Use shall mean, for the Licensed Product OsteoMorphin is Dentistry and Periodontics in humans, and, Orthopedic use in humans, and Therapeutic use in animals.
The Field of Use shall mean, for the Licensed Product, One-Stop-Implant for Therapeutic use in the oral cavity in humans and animals.
IPSCIO Record ID: 3101
The licensed technologies include the rights to issued patents and patents pending in the United States and international markets.
The AxoGuardÂ® Nerve Protector is indicated for the repair of peripheral nerve injuries where there is no gap. The device is supplied sterile and is intended for one-time use.
In order to improve surgical reconstruction and regeneration of peripheral nerves, the Licensee has developed and licensed technologies, which are used in its products. Its product portfolio includes AvanceÂ® Nerve Graft which the Licensee believes is the first and only commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed) AxoGuardÂ® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuardÂ® Nerve Protector, an implant that protects nerves during the body's healing process after surgery.
IPSCIO Record ID: 5492
2760-40-101 Disposable Processing Kit – Single
2760-40-102 Disposable Processing Kit – Double
Disposable Processing Kits contain the items required for containing blood during processing in the centrifuge
2760-40-310 Centrifuge and Cart Assembly
2760-40-200 Applicator Kit